Related Experiment Video

Updated: Jun 1, 2026

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

Factors affecting duration of chronic fatigue syndrome in pediatric patients

Dmitriy Petrov1, Daniel Marchalik, Michael Sosin

  • 1UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Indian Journal of Pediatrics
|May 28, 2011
PubMed

Insights

High Body-Mass Index (BMI) is linked to longer chronic fatigue syndrome (CFS) duration in children and adolescents. This finding aids in understanding pediatric CFS progression.

Area of Science:

  • Pediatric Infectious Diseases
  • Immunology
  • Clinical Medicine

Background:

  • Chronic Fatigue Syndrome (CFS) in pediatric patients presents a diagnostic and management challenge.
  • Understanding factors influencing the duration of CFS is crucial for effective treatment strategies.
  • Previous research has not definitively identified predictors for prolonged pediatric CFS.

Purpose of the Study:

  • To identify demographic, clinical, and laboratory factors associated with the duration of chronic fatigue syndrome (CFS) in pediatric patients.
  • To investigate the impact of specific infections and patient characteristics on CFS symptom persistence.

Main Methods:

  • Retrospective cohort study of 53 pediatric patients diagnosed with CFS.
  • Analysis of demographic, clinical, and laboratory data, including seropositivity for Borrelia burgdorferi and Epstein-Barr virus.
  • Regression modeling to assess the association between various factors and CFS duration, adjusted for age, gender, and infection status.

Main Results:

  • Headaches and sleep disturbances were common co-occurring symptoms alongside fatigue in pediatric CFS.
  • A significant proportion of patients (66%) were seropositive for Borrelia burgdorferi and/or Epstein-Barr virus.
  • Higher Body-Mass Index (BMI) was significantly associated with a prolonged duration of CFS symptoms (P < 0.04).

Conclusions:

  • Elevated Body-Mass Index (BMI) is a significant predictor of longer chronic fatigue syndrome duration in pediatric populations.
  • These findings suggest BMI as a potential target for interventions aimed at shortening CFS duration in adolescents.
  • Further research is warranted to explore the mechanisms linking BMI to CFS chronicity.
Abstract

More Related Videos

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...